Sun Pharma launches Fexuclue® for erosive esophagitis; resolves US litigation

Sun Pharmaceutical Industries (BSE: 524715) announced the launch of Fexuclue® (Fexuprazan) tablets in India as a new treatment for adults with Erosive Esophagitis of all grades. Fexuclue®, a potassium-competitive acid blocker (PCAB), offers rapid action, stable gastric acid suppression regardless of food intake, and an extended half-life compared to other P-CABs. Sun Pharma obtained rights to manufacture and commercialize Fexuclue® from Daewoong Pharmaceutical Co Ltd, Korea, and under the agreement, Daewoong will be entitled to upfront and milestone payments, including royalties.